To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Type d'étude
Type d'étude
Inscription (Anticipé)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Xiaodong Wang
- Numéro de téléphone: +86 021-60673947
- E-mail: wang_xiaodong@mail.ecspc.com
Lieux d'étude
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chine
- Recrutement
- Harbin Medical University Cancer Hospital
-
Contact:
- Yanqiao Zhang, Professor
- Numéro de téléphone: 13845120210
- E-mail: yanqiaozhang@126.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female patients with an age of 18~75years (inclusive).
- Confirmed histologic or cytologic diagnosis of an advanced and/or metastatic solid tumor.
- At least one measurable lesion as defined by RECIST version 1.1.
- Eastern Cooperative Oncology Group Performance Status 0 or 1.
- Life expectancy ≥3 months.
- Major organ function within 14 days prior to treatment meets the following criteria (no blood transfusion, Erythropoietin(EPO), Granulocyte Colony Stimulating Factor(G-CSF) or other medical support): Absolute Neutrophil Count(ANC)≥1.5×10^9/L,Platelet(PLT)≥90×10^9/L,Hemoglobin(Hb)≥100g/L or≥6.2 mmol/L;Creatinine(Cr)≤1.5×upper limit of normal(ULN) and creatinine clearance rate≥50mL/min;Total Bilirubin(TBIL)≤1.5×ULN; Prothrombin time(PT)≤1.5×ULN , Activated Partial Thromboplastin Time(APTT)≤1.5×ULN , Aspartate Aminotransferase(AST)/Alanine Aminotransferase(ALT)≤2.5 × ULN.
- Signed informed consent form.
Exclusion Criteria:
- Chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor treatment within 4 weeks prior to the first dose of the study drug, or administration of other investigational agents within 4 weeks or 5 half-lives prior to the first dose of the study drug, whichever is longer.
- Major surgery or significant trauma within 4 weeks prior to the first dose of the study drug.
- Adverse reactions from the previous anti-tumor treatment have not yet recovered to ≤ level 1 based on CTCAE 5.0。
- Have a history of severe cardiovascular and cerebrovascular disease.
- Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence shows that the patient's central nervous system metastasis or meningeal metastasis has not been controlled and not suitable for the study according to the judgment of the investigator.
- Known history of hypersensitivity to test drug components.
- Patients with recent active bleeding or a history of bleeding.
- Those with coagulation disorders or taking thrombolytic, anticoagulant or antiplatelet agglutination drugs.
- Gastrointestinal perforation, abdominal fistula, or intra-abdominal abscess within 6 months prior to first dose; or currently under investigator's judgement there are high risk factors for hollow organ perforation/fistula formation).
- Inability to swallow the drug orally, or a condition that seriously affects gastrointestinal absorption in the judgment of the investigator.
- Irritable bowel syndrome with signs/symptoms requiring medication.
- Persistent active diarrhea requiring medical treatment.
- Concomitant use of strong CYP3A4 inhibitors or inducers, strong CYP2D6 inhibitors and strong P-gp inhibitors within 14 days prior to the first dose of the study drug.
- History of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency, or organ transplant history.
- Known Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or other active viral infection.
- Male and female patients of childbearing potential do not agree to use suitable method of contraception during the treatment and 6 months after the last dose of study medication; female patients do not have negative results of serum/urine pregnancy test within 7 days prior to enrollment and would be breastfeeding.
- Not suitable for this study as determined by the investigator due to other reasons.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: SYHX2001
SYHX2001 will be administered orally.
|
SYHX2001 tablets, oral
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Dose limiting toxicities (DLT) in stage Ⅰ
Délai: Baseline through Day 28
|
Baseline through Day 28
|
|
Maximum tolerated dose (MTD) in stage Ⅰ
Délai: Baseline through Day 28
|
Baseline through Day 28
|
|
Recommended phase 2 dose (RP2D)
Délai: Baseline through approximately 2 years
|
Baseline through approximately 2 years
|
|
Incidence and severity of adverse events in stage Ⅰ
Délai: Baseline through approximately 2 years
|
Baseline through approximately 2 years
|
|
Overall response rate (ORR) in stage Ⅱ
Délai: Up to approximately 2 years
|
Up to approximately 2 years
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of SYHX2001
Délai: Baseline and up to approximately 2 years
|
Baseline and up to approximately 2 years
|
|
|
Area under the plasma concentration-time curve (AUC) extrapolated from time zero to infinity (AUC[0-inf]) of SYHX2001
Délai: up to approximately 2 years
|
up to approximately 2 years
|
|
|
AUC from time zero to the last quantifiable concentration after dosing (AUC[0-t]) of SYHX2001
Délai: up to approximately 2 years
|
up to approximately 2 years
|
|
|
Terminal phase half-life (t1/2) of SYHX2001
Délai: up to approximately 2 years
|
up to approximately 2 years
|
|
|
Oral clearance (CL/F) of SYHX2001
Délai: up to approximately 2 years
|
up to approximately 2 years
|
|
|
PFS Progression-free survival (PFS)
Délai: up to approximately 2 years
|
PFS is defined as the time from first dose until radiographic progression per standard criteria or death due to any cause, whichever is earlier.
|
up to approximately 2 years
|
|
Duration of Response (DOR)
Délai: up to approximately 2 years
|
DOR is defined as the time from first evidence of response (complete response or partial response per RECIST 1.1) to earlier date of disease progression or death due to any cause.
|
up to approximately 2 years
|
|
Number of patients with any adverse events(AEs) and serious adverse events(SAEs) in stage Ⅱ
Délai: up to approximately 2 years
|
up to approximately 2 years
|
|
|
Change from Baseline in symmetrical arginine dimethylation (SDMA) as a pharmacodynamics(PD) measure
Délai: Baseline and up to approximately 2 years
|
Baseline and up to approximately 2 years
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement primaire
Achèvement de l'étude (Anticipé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- SYHX2001C101
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .